4 completed, 2 active not recruiting. 3 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Alkylating Agents: new trials by email Literature Review of Alkylating Agents trials Research Report on Alkylating Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Disulfiram in Recurrent Glioblastoma Disulfiram, Copper, Alkylating Agents - Glioma, Glioblastoma | Phase 2 / Phase 3 | Completed | Sahlgrenska University Hospital | 88 | 2017-01-01 | 2021-03-18 |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck Cisplatin, Stereotactic Body Radiation Therapy (SBRT) - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2014-07-16 | 2023-01-19 |
| Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator - Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT) | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2010-08-01 | 2026-09-09 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer BIIB022 With Paclitaxel and Carboplatin - Non-Small Cell Lung Cancer | Phase 1 | Completed | Biogen | 18 | 2009-10-01 | 2013-09-16 |
| Multicenter Uveitis Steroid Treatment (MUST) Trial fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed - Uveitis | Phase 4 | Completed | JHSPH Center for Clinical Trials | 255 | 2005-09-01 | 2016-11-25 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Desmoplastic Small Round Cell Tumor (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uveitis (1)
Biogen (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · JHSPH Center for Clinical Trials (1) · Memorial Sloan Kettering Cancer Center (1) · Sahlgrenska University Hospital (1) · Stanford University (1)
United States (5) · Australia (1) · Norway (1) · Sweden (1) · United Kingdom (1)
Asgeir S Jakola, MD, PhD (1) · Douglas Jabs, MD, MBA (1) · Emily Slotkin, MD (1) · Everett Meyer, MD,PhD (1) · Janet T Holbrook, PhD, MPH (1) · Jimmy Caudell, M.D., Ph.D. (1) · John Kempen, MD, PhD (1) · Michael Altaweel, MD (1)
PMID 21652026, PMID 21840602, PMID 21861971, PMID 22247489, PMID 22409563, PMID 23163490, PMID 25115882, PMID 26501236, PMID 26798977, PMID 28477440, PMID 30647912, PMID 32918964, PMID 37000452
U10EY014660 (1)